Search results
Showing 301 to 315 of 379 results for lung cancer
Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655.
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
This guidance has been updated and replaced by NICE technology appraisal guidance 1071.
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development Reference number: GID-TA10935 Expected publication date: TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Discontinued Reference number: GID-TA11569
Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
This guidance has been updated and replaced by NICE technology appraisal guidance 713.
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)
This guidance has been updated and replaced by NICE technology appraisal guidance 1021.
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
This guidance has been updated and replaced by NICE technology appraisal guidance 1103.
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Discontinued Reference number: GID-TA11302
Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)
This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)
This guidance has been updated and replaced by NICE technology appraisal guidance 531.
19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at moderately increased risk...
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].